SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CIO COMPUTERIZED THERMAL IMAGING (formerly COII)
CIO 6.9900.0%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: ripalip12/21/2000 4:09:24 AM
   of 23
 
****** CTI Granted Patent for Pain Treatment ******
CTI Granted Patent for Pain Treatment
Techniques Combine Use of Infrared Therapy and Thermal Imaging

LAYTON, Utah, Nov. 29 /PRNewswire/ --
Computerized Thermal Imaging, Inc. (OTC Bulletin Board: COII) announced today
that Bales Scientific, a wholly-owned subsidiary, has been granted a patent
covering techniques designed to reduce or eliminate pain by the application of
infrared therapy while monitoring the process as it is being conducted. The
techniques involve the use of the CTI Photonic Stimulator to apply infrared
energy to a patient while using the Thermal Image Processor to monitor the
patient's response to the therapy.
"I am pleased to receive patent protection for this process,"
said David Packer, company president. "The protection of our intellectual
property is of vital importance to CTI, and we are excited to have patent
protection for these unique techniques."
The Photonic Stimulator is a therapy tool that emits infrared energy,
which penetrates the skin to stimulate increased blood flow and circulation,
thereby providing safe, temporary relief of aches and pains. The Thermal
Image Processor is a high-resolution thermal camera that provides a
"real-time," physiological view of the body. The thermal images are presented
instantly on a computer screen that vividly displays temperature differentials
by color-enhanced images of the body. Both the Photonic Stimulator and the
Thermal Image Processor have received FDA 510K clearance.
The Photonic Stimulator and the Thermal Image Processor are the same tools
used, along with the now patented techniques, to treat members of the
U.S. Track and Field team leading up to and during the recent summer Olympics.
Physicians and therapists can use these same tools to obtain more information
about a patient's physical condition, to provide therapy and to monitor
patient response to therapy.
It is common for patients to experience pain in an area other than the
area that is the root cause. Using the new technique, the thermal imager is
used to guide the practitioner in determining which areas to treat. Based on
those results and clinical examination, infrared therapy is then applied.
Thermal imaging continues to be used during the treatment to monitor the
patient's response to the therapy. Monitoring the process allows the
practitioner to discontinue the application of infrared energy once the
desired effect has been achieved. Although additional infrared therapy is not
known to cause any harm to the patient, it would unnecessarily extend the
duration and cost of the treatment.
CTI is in business to improve the quality of life through the development
and deployment of thermal imaging and associated technologies. More
Information about the Photonic Stimulator and the Thermal Image Processor can
be found at the Bales Scientific Web site at www.balesscientific.com .
Information about CTI can be found at www.cti-net.com or by calling CTI Public
Affairs at 801-926-1113.
Except for historical information contained herein, the matters discussed
in this news release are forward-looking statements that involve risks and
uncertainties. The forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
The Company undertakes no obligation to update any of the forward-looking
statements contained in its press releases. In addition to the factors set
forth above, other important factors that could cause actual results to differ
materially include, but are not limited to, technical risks associated with
new technology development, government regulatory approvals and access to
working capital. Additional information concerning factors that could cause
actual results to differ materially from those in the forward-looking
statements is contained from time to time in the Company's SEC filings.
Copies of these filings may be obtained by contacting the Company or the SEC.
The Company undertakes no obligation to update any of the forward-looking
statements contained in its press releases.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext